Summary

Market Overview
The Global Molecular Oncology Diagnostics Market is anticipated to expand from USD 3.76 billion in 2025 to USD 8.39 billion by 2031, reflecting a compound annual growth rate of 14.31%. This field involves laboratory techniques designed to detect disease presence and assess risk by analyzing specific molecules like DNA, RNA, and proteins in fluid or tissue samples, ultimately aiding in treatment formulation, recurrence tracking, and evaluating therapy effectiveness. Market advancement is largely driven by rising global cancer rates and a surging need for personalized medicine, which requires accurate molecular profiling. Expansion is additionally bolstered by a growing emphasis on early diagnosis, thorough risk assessment, and the incorporation of molecular diagnostics within clinical trials. Highlighting the ongoing demand for sophisticated diagnostic solutions, the College of American Pathologists projects that the United States will see over two million new cancer cases in 2026.
However, the high expenses linked to cutting-edge molecular testing platforms and equipment pose a major obstacle to market growth. These significant financial requirements, combined with ongoing gaps in reimbursement coverage for novel genomic assays, place a disproportionate burden on developing nations and smaller laboratories. As a result, the widespread availability and integration of these vital diagnostic technologies are considerably limited.
Market Driver
Rising cancer rates worldwide serve as a primary catalyst for the molecular oncology diagnostics market, driving the need for sophisticated tools to assist in early detection, prognosis, and treatment direction. As global demographics shift toward aging populations and risk factor exposures change, the overall cancer burden continues to grow, fostering a steady requirement for advanced diagnostic options. Research featured in The Lancet and referenced by the Institute for Health Metrics and Evaluation in its September 2025 publication, "Q&A: Global burden of cancer and forecasts to 2025," noted over 18 million new cancer cases globally in 2023. This immense volume of diagnoses emphasizes the vital necessity for molecular testing capable of precisely characterizing cancer types and their unique molecular signatures, a critical component for optimizing patient care and ongoing monitoring.
Market growth is additionally fueled by the increasing embrace of personalized and precision oncology, methodologies that depend intrinsically on comprehensive molecular profiling to customize therapies based on a patient's distinct traits. Consequently, there is a surging need for companion diagnostics designed to pinpoint specific biomarkers and facilitate targeted treatments. Major industry participants are directing substantial capital toward this transition to accommodate the rising demand. In an April 2025 BioSpace article titled 'Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years,' Roche revealed plans to channel USD 50 billion into the U.S. over five years to establish new manufacturing and research facilities for its advanced diagnostics and medical portfolio. This investment demonstrates how deeply molecular data is becoming embedded in standard treatment protocols. Moreover, Roche's investor data indicates that 31 billion diagnostic tests were supplied globally in 2025, illustrating the widespread utilization of diagnostic tools across modern healthcare and their escalating relevance in the field of oncology.
Market Challenge
High expenses tied to sophisticated molecular testing equipment and platforms act as a formidable hurdle to the expansion of the global molecular oncology diagnostics market. The massive capital investments required to secure such advanced machinery impose a heavy financial burden, especially on laboratories in developing nations and those operating on a smaller scale. Additionally, ongoing deficiencies in reimbursement policies for cutting-edge genomic assays worsen the situation, hindering healthcare providers from fully recouping the substantial expenses incurred while administering these intricate and specialized diagnostic procedures.
These monetary constraints directly hinder broad accessibility to vital diagnostic advancements. The American Clinical Laboratory Association warns that unless Congress intervenes, roughly 800 laboratory tests will face rate reductions of up to 15% under the Clinical Laboratory Fee Schedule starting January 31, 2026. Such cuts in reimbursement pose a threat to the financial stability of laboratories, limiting their ability to fund new molecular oncology tests or broaden their current offerings. Ultimately, this dynamic stifles the uptake of modern diagnostic instruments, limits market reach, and decelerates the overarching growth trajectory of the molecular oncology diagnostics sector.
Market Trends
A defining development in molecular oncology diagnostics is the widespread adoption of Next-Generation Sequencing (NGS) for extensive genomic profiling. This shift is marked by the growing incorporation of comprehensive genomic evaluations into standard clinical practice, transitioning away from single-gene assessments to deliver a complete picture of a tumor's genetic makeup. Thorough genomic profiling facilitates the discovery of actionable mutations, directs customized therapeutic interventions, and offers a more precise understanding of how the disease advances. Highlighting this momentum, 1stOncology reported on February 5, 2026, that Illumina's Q4 2025 earnings showed a 20% increase in clinical consumables revenue outside of China, a surge attributed to the wider embrace of sequencing-reliant diagnostics.
Another revolutionary trend heavily influencing the industry is the rising utilization of liquid biopsies for the non-invasive management of cancer. By examining circulating tumor DNA and other biomarkers in blood samples, liquid biopsies present a less intrusive substitute for conventional tissue biopsies when diagnosing cancer, tracking treatment efficacy, and monitoring for relapse. This approach is particularly advantageous when securing tissue samples is challenging or when continuous observation is necessary, granting immediate perspective on how a tumor is evolving. Demonstrating this rising clinical acceptance and practicality, Natera experienced a 54.7% year-over-year jump in its oncology test volume during the fourth quarter of 2025, processing roughly 233,300 tests, as noted in a February 26, 2026, Stock Titan report detailing the company's 8-K filing on revenue and cash flow.

Key Market Players
* Sysmex Corporation
* F. Hoffmann-La Roche Ltd.
* Myriad Genetics, Inc.
* HTG Molecular Diagnostics, Inc.
* Danaher Corporation
* QIAGEN N.V.
* Bio-Rad Laboratories, Inc.
* Agilent Technologies, Inc.
* Illumina, Inc.
* Bayer AG

Report Scope
In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

# Molecular Oncology Diagnostics Market, By Product Type
* Instruments
* Kits and Assays
* Software
# Molecular Oncology Diagnostics Market, By Technology
* Fluorescence In-Situ Hybridization (FISH)
* Next-Generation Sequencing (NGS)
* Polymerase Chain Reaction (PCR)
* Immunohistochemistry (IHC)
* Flow Cytometry
* Other Technologies
# Molecular Oncology Diagnostics Market, By Application
* Research
* Clinical
# Molecular Oncology Diagnostics Market, By Cancer Type
* Solid Tumor
* Blood Cancers
# Molecular Oncology Diagnostics Market, By End User
* Hospitals and Diagnostic Centers
* Reference Laboratories
* Pharmaceutical and Biotechnology Companies
* Academic
* Research Institutes
# Molecular Oncology Diagnostics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.
Available Customizations:
Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Molecular Oncology Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Instruments, Kits and Assays, Software)
5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, Other Technologies)
5.2.3. By Application (Research, Clinical)
5.2.4. By Cancer Type ({Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma,, other Hematological Malignancies)})
5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic, Research Institutes)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Molecular Oncology Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Technology
6.2.3. By Application
6.2.4. By Cancer Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Molecular Oncology Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Application
6.3.1.2.4. By Cancer Type
6.3.1.2.5. By End User
6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Application
6.3.2.2.4. By Cancer Type
6.3.2.2.5. By End User
6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Application
6.3.3.2.4. By Cancer Type
6.3.3.2.5. By End User
7. Europe Molecular Oncology Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Technology
7.2.3. By Application
7.2.4. By Cancer Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Application
7.3.1.2.4. By Cancer Type
7.3.1.2.5. By End User
7.3.2. France Molecular Oncology Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Application
7.3.2.2.4. By Cancer Type
7.3.2.2.5. By End User
7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Application
7.3.3.2.4. By Cancer Type
7.3.3.2.5. By End User
7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Application
7.3.4.2.4. By Cancer Type
7.3.4.2.5. By End User
7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Application
7.3.5.2.4. By Cancer Type
7.3.5.2.5. By End User
8. Asia Pacific Molecular Oncology Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Technology
8.2.3. By Application
8.2.4. By Cancer Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Molecular Oncology Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Application
8.3.1.2.4. By Cancer Type
8.3.1.2.5. By End User
8.3.2. India Molecular Oncology Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Application
8.3.2.2.4. By Cancer Type
8.3.2.2.5. By End User
8.3.3. Japan Molecular Oncology Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Application
8.3.3.2.4. By Cancer Type
8.3.3.2.5. By End User
8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Application
8.3.4.2.4. By Cancer Type
8.3.4.2.5. By End User
8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Application
8.3.5.2.4. By Cancer Type
8.3.5.2.5. By End User
9. Middle East & Africa Molecular Oncology Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Technology
9.2.3. By Application
9.2.4. By Cancer Type
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Application
9.3.1.2.4. By Cancer Type
9.3.1.2.5. By End User
9.3.2. UAE Molecular Oncology Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Application
9.3.2.2.4. By Cancer Type
9.3.2.2.5. By End User
9.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Application
9.3.3.2.4. By Cancer Type
9.3.3.2.5. By End User
10. South America Molecular Oncology Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Technology
10.2.3. By Application
10.2.4. By Cancer Type
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Application
10.3.1.2.4. By Cancer Type
10.3.1.2.5. By End User
10.3.2. Colombia Molecular Oncology Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Application
10.3.2.2.4. By Cancer Type
10.3.2.2.5. By End User
10.3.3. Argentina Molecular Oncology Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Application
10.3.3.2.4. By Cancer Type
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Molecular Oncology Diagnostics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Sysmex Corporation
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Myriad Genetics, Inc.
15.4. HTG Molecular Diagnostics, Inc.
15.5. Danaher Corporation
15.6. QIAGEN N.V.
15.7. Bio-Rad Laboratories, Inc.
15.8. Agilent Technologies, Inc.
15.9. Illumina, Inc.
15.10. Bayer AG
16. Strategic Recommendations
17. About Us & Disclaimer